Chelatexx Test Agent for Decreased GI Adverse Events compared to Orlistat API

Trial Profile

Chelatexx Test Agent for Decreased GI Adverse Events compared to Orlistat API

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Orlistat (Primary)
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 According to Callitas Therapeutics media release, M Pharmaceutical changed its name to Callitas Therapeutics
    • 19 Sep 2016 New trial record
    • 11 Aug 2016 According to M-Pharmaceuticals media release, Ronald J. Thompson MD was the principal investigator and James M. Thompson was the secondary Investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top